*Therapeutic Approach to NAFLD-NASH DOI: http://dx.doi.org/10.5772/intechopen.107487*

[14] Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010;**362**(18):1675-1685

[15] Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, et al. Non-alcoholic steatohepatitis clinical research network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 2013;**38**(2):134-143

[16] Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2019;**17**(13):2776-2784

[17] Jiang ZG, Feldbrügge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Alimentary Pharmacology & Therapeutics. 2016;**43**(6):734-743

[18] Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. Journal of Hepatology. 2015;**63**(3):705-712

[19] Athyros V, Tziomalos K, Katsiki N, Gossios T, et al. The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: A post hoc analysis of the GREACE study. Current Vascular Pharmacology. 2013;**11**(5):779-784

[20] Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA. 2005;**294**(19):2437-2445. DOI: 10.1001/ jama.294.19.2437

[21] Athyros G et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): A prospective-randomized study in middle aged men and women. Current Vascular Pharmacology. 2011;**9**(6):647-657

[22] Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: A post hoc analysis of the randomised ATTEMPT study. Archives of Medical Science. 2011;**7**(5):796-805

[23] Sfikas G, Psallas M, Koumaras C, Imprialos K, Perdikakis E, Doumas M, et al. Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease/nonalcoholic steatohepatitis in military personnel. Do genetics play a role? Current Vascular Pharmacology. 2021;**19**(5):572-581

[24] Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Hepatology. 2012;**56**(4):944-951

[25] Masterton GS, Plevris JN, Hayes PC. Omega-3 fatty acids–a promising novel therapy for non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics. 2010;**31**(7):679-692

[26] Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Experimental in Diabetes Research. 2012;**2012**:716

[27] Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomedical Reports. 2013;**1**(1):57-64

[28] Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebocontrolled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology. 2008;**135**(1):100-110

[29] Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;**39**(1):188-196

[30] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England Journal of Medicine. 2006;**355**(22):2297-2307. DOI: 10.1056/NEJMoa060326

[31] Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial. Annals of Internal Medicine. 2016;**165**(5):305-315

[32] Ratziu V et al. Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;**150**(5):1147-1159

[33] Van Meeteren W, Menso J, Drenth JPH, Tjwa ETTL. Elafibranor: A potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs. 2020;**29**(2):117-123

[34] Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebocontrolled phase 2 study. The Lancet. 2016;**387**(10019):679-690

[35] Cusi K. Incretin-based therapies for the Management of Nonalcoholic Fatty Liver Disease in patients with type 2 diabetes. Hepatology. 2019;**69**(6):2318-2322

[36] Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. NN9931-4296 investigators. A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis. The New England Journal of Medicine. 2021;**384**(12):1113-1124

[37] Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H, et al. The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice. International Journal of Molecular Sciences. 2015;**16**(12):29207-29218

[38] Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes & Metabolism. 2019;**45**(3):213-223

[39] Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. Journal of Gastroenterology. 2018;**53**(3):362-376

*Therapeutic Approach to NAFLD-NASH DOI: http://dx.doi.org/10.5772/intechopen.107487*

[40] Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, et al. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: The long-term effects on clinical features and liver histopathology. Internal Medicine. 2020;**59**(16):1931-1937

[41] Venetsanaki V, Karabouta Z, Polyzos SA. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology. 2019;**863**:172661

[42] Discovery of Tropifexor (LJN452). A highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). Journal of Medicinal Chemistry. 2017;**60**(24):9960-9973

[43] Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Annals of Translational Medicine. 2015;**3**(1):5

[44] Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology (Baltimore, MD). 2017;**65**(1):350-362. DOI: 10.1002/ hep.28709

[45] Li X et al. Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR-β Agonist, in High Fat Diet Induced NASH SD Rats. Netherlands: Elsevier; 2021

[46] Stiede K, Miao W, Blanchette HS, Beysen C, Harriman G, Harwood HJ Jr, et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study. Hepatology. 2017;**66**(2):324-334

[47] Aljohani AM, Syed DN, Ntambi JM. Insights into stearoyl-CoA desaturase-1 regulation of systemic metabolism. Trends in Endocrinology and Metabolism. 2017;**28**:831-842

[48] Kotronen A, Seppänen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes. 2009;**58**(1):203-208

[49] Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nature Reviews Drug Discovery. 2016;**15**(1):51-69

[50] Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;**45**(6):1366-1374

[51] Saxena A, Chidsey K, Somayaji V, Ogden A, Duvvuri S. Diacylglycerol acyltransferase 2 (DGAT2) inhibitor PF-06865571 reduces liver fat by MRI-PDFF after 2 weeks in adults with NAFLD. Hoboken, NJ: Wiley;

[52] Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology. 2016;**13**(7):412-425

[53] Safari Z, Gérard P. The links between the gut microbiome and nonalcoholic fatty liver disease (NAFLD). Cellular and Molecular Life Sciences. 2019;**76**(8):1541-1558
